Ambrx Biopharma Cayman, Inc. financial data

Location
La Jolla, CA
Fiscal year end
31 December

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 434,070,056 shares
Common Stock, Shares, Outstanding 432,227,488 shares +59.9%
Common Stock, Value, Issued 43,000 USD +59.3%
Weighted Average Number of Shares Outstanding, Basic 391,283,214 shares +44.8%
Weighted Average Number of Shares Outstanding, Diluted 391,283,214 shares +44.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1,123,000 USD -13.5%
Revenue from Contract with Customer, Excluding Assessed Tax 1,123,000 USD -13.5%
Research and Development Expense 14,393,000 USD -20.3%
General and Administrative Expense 5,900,000 USD +22.3%
Operating Income (Loss) -19,170,000 USD +33.4%
Nonoperating Income (Expense) 1,649,000 USD +23.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17,521,000 USD +39%
Income Tax Expense (Benefit) 305,000 USD +1.4%
Net Income (Loss) Attributable to Parent -17,826,000 USD +38.2%
Earnings Per Share, Basic -0.05 USD/shares +54.5%
Earnings Per Share, Diluted -0.05 USD/shares +54.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 228,265,000 USD +2.5%
Accounts Receivable, after Allowance for Credit Loss, Current 81,000 USD -94.5%
Other Assets, Current 981,000 USD -0.51%
Assets, Current 241,413,000 USD +99.5%
Property, Plant and Equipment, Net 3,195,000 USD +1.6%
Operating Lease, Right-of-Use Asset 10,044,000 USD -15.3%
Intangible Assets, Net (Excluding Goodwill) 24,935,000 USD -2.5%
Other Assets, Noncurrent 357,000 USD -23.4%
Assets 279,944,000 USD +54.8%
Accounts Payable, Current 6,362,000 USD +11.7%
Accrued Liabilities, Current 9,556,000 USD -38.7%
Liabilities, Current 18,179,000 USD -29.4%
Contract with Customer, Liability, Noncurrent 1,749,000 USD -58.8%
Deferred Income Tax Liabilities, Net 880,000 USD 0%
Operating Lease, Liability, Noncurrent 9,163,000 USD -18.6%
Liabilities 29,564,000 USD -24.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -953,000 USD +5.4%
Retained Earnings (Accumulated Deficit) -324,756,000 USD -22.5%
Stockholders' Equity Attributable to Parent 250,380,000 USD +76.5%
Liabilities and Equity 279,944,000 USD +54.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12,967,000 USD +49.5%
Net Cash Provided by (Used in) Financing Activities 77,221,000 USD
Net Cash Provided by (Used in) Investing Activities 29,554,000 USD
Common Stock, Shares Authorized 950,000,000 shares +90%
Common Stock, Shares, Issued 432,227,488 shares +59.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 93,808,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 228,930,000 USD +2.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Depreciation 200,000 USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 9,216,000 USD +10%
Operating Lease, Liability, Current 1,854,000 USD +40.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Preferred Stock, Shares Issued 0 shares
Operating Lease, Payments 673,000 USD +2.3%
Additional Paid in Capital 576,046,000 USD +41.2%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 200,000 USD -50%
Share-based Payment Arrangement, Expense 2,886,000 USD +53.6%